Skip Navigation

JNCI Journal of the National Cancer Institute 2003 95(23):1743; doi:10.1093/jnci/95.23.1743
© 2003 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Wang, L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Wang, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2003 Oxford University Press

NEWS

In Brief

Linda Wang

The first 10% of the full text of this article appears below.

Tamoxifen/Raloxifene Study Can Be Completed With Fewer Participants

The Study of Tamoxifen and Raloxifene (STAR) can be completed with 3,000 fewer postmenopausal women volunteers than it originally estimated, according to the National Surgical Adjuvant Breast and Bowel Project, the group conducting the trial.

STAR is designed to compare whether the drug raloxifene . . . [Full Text of this Article]

New Guidelines Issued for Unrelated Marrow Transplants

ASCO Updates Guidelines for Bisphosphonates in Breast Cancer


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?